Abstracts tagged "risk factors"

Abstract Number: 1436 • ACR Convergence 2020
Incidence Rate, Predictors and Outcome of Stroke in Patients with ANCA Associated Vasculitis – A Population-based Study
Dennis Tabakovic¹, Rona Smith², David Jayne³ and Aladdin Mohammad⁴, ¹Lund University, Lund, Skane Lan, Sweden, ²University of Cambridge, Cambridge, United Kingdom, ³Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom, ⁴Lund University, Lund, Sweden. Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Lund, Sweden
Background/Purpose: To study the incidence rate, predictors and outcome of stroke in patients with ANCA-associated vasculitis (AAV) within a defined population in southern Sweden.Methods: The…
Abstract Number: 1978 • ACR Convergence 2020
Prevalence and Factors Associated with Patient-Physician Discordance Among RA Patients Initiating Advanced Therapy
Jeffrey Curtis¹, Rose Medeiros², I-Heng Lee³, Rachel Mackey⁴, Richard Haubrich³, Hao Hu⁵, Jeffrey Greenberg⁶ and Alicea Wu³, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Corrona, LLC, Waltham, MA, ³Gilead Sciences, Foster City, CA, ⁴Corrona, LLC and University of Pittsburgh, Waltham, MA, ⁵Gilead Sciences, Inc., Foster City, CA, ⁶Corrona, LLC and NYU School of Medicine, Waltham, MA
Background/Purpose: Some rheumatoid arthritis (RA) patients rate their disease activity worse than their physician does, but recent prevalence and factors associated with such discordance have…
Abstract Number: 465 • 2019 ACR/ARP Annual Meeting
Prognostic Factors and Clinical Outcome Modifiers in Patients with Rheumatoid Arthritis: A Review
Leticia Ferri¹, Grace Crocket ², Xue Han ¹, Boris Breznen ³ and Mir Sohail Fazeli ³, ¹Bristol-Myers Squibb Company, Princeton, NJ, ²Bristol-Myers Squibb; Rutgers University, New York City, NY, ³Doctor Evidence, Santa Monica, CA
Background/Purpose: The current goal in treatment of RA is to deliver therapies tailored to individual patients’ characteristics. Establishing disease prognosis is a crucial first step…
Abstract Number: 2327 • 2019 ACR/ARP Annual Meeting
Cardiovascular Disease in Rheumatoid Arthritis: Risk Factors and the Role of Auto-antibodies
Leticia Ferri¹, Grace Crocket ², Yuting Kuang ³, Boris Breznen ⁴ and Mir Sohail Fazeli ⁴, ¹Bristol-Myers Squibb Company, Princeton, NJ, ²Bristol-Myers Squibb; Rutgers University, New York City, NY, ³Doctor Evidence, Doctor Evidence, CA, ⁴Doctor Evidence, Santa Monica, CA
Background/Purpose: Shorter life expectancy in RA patients has in part been associated with an increased incidence of cardiovascular disease (CVD). This literature review summarizes the…
Abstract Number: 2349 • 2019 ACR/ARP Annual Meeting
Epidemiology, Risk/Prognostic Factors, and Treatment Landscape in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Systematic Literature Review
Xue Han¹, Leticia Ferri ¹, Grace Crocket ², Sophie Yoon ³, Tracy Slanger ³ and Mir Sohail Fazeli ³, ¹Bristol-Myers Squibb Company, Princeton, NJ, ²Bristol-Myers Squibb; Rutgers University, New York City, NY, ³Doctor Evidence, Santa Monica, CA
Background/Purpose: Interstitial lung disease (ILD) is the most common lung manifestation of RA and the 2nd leading cause of death in RA patients.1,2 The purpose…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].